Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...
AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large ...
Eli Lilly's noncovalent BTK inhibitor Jaypirca has been cleared by the FDA in its first frontline indication for chronic ...
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, ...
Chronic lymphocytic leukemia (CLL), the most common leukemia of adults in Western countries, is standing at a genuine ...
Health and Me on MSN
FDA approves targeted cancer drug as first-line treatment for CLL that cuts progression risk by 80%
The US Food and Drug Administration (FDA) recently approved pirtobrutinib for people with previously untreated chronic ...
Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced that the first patient has been dosed in a Phase III clinical ...
Zacks Investment Research on MSN
FDA expands Eli Lilly's blood cancer drug label in first-line setting
Eli Lilly LLY announced that the FDA has expanded the label of its oral cancer drug Jaypirca (pirtobrutinib) to include a new ...
DeLLphi-305 randomized 563 nonprogressing ES-SCLC patients post induction durvalumab plus platinum/etoposide to durvalumab maintenance with or without tarlatamab, with overall survival as the primary ...
BeOne Medicines, a global oncology company, today announced the successful completion of negotiations with the pan-Canadian ...
Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring ...
Tucatinib FDA approval expands TUKYSA into first-line HER2+ metastatic breast cancer maintenance after HER2CLIMB-05 improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results